pharmaceuticals

pharmaceuticals Articles

Catalyst Pharmaceuticals saw its shares get halved just Tuesday morning alone, following a business update regarding its Lambert-Eaton myasthenic syndrome treatment.
Typically each year, the first quarter is the slowest for biotech stocks. SunTrust Robinson Humphrey has four stocks rated Buy that should come in fine when numbers are released.
Attaining a certain drug can mean the difference between life and death for millions of Americans. These essential products also help generate billions for drug manufacturers. Pharmaceutical...
Eli Lilly is set to release its first-quarter earnings report before the markets open on Tuesday.
Aralez Pharmaceuticals saw its stock take a solid uptick early on Monday following a key approval in Canada.
Sarepta Therapeutics shares got crushed on Thursday and then exploded on Friday following the FDA view on its Duchenne muscular dystrophy treatment.
Parnell Pharmaceuticals saw its shares take a sharp uptick into the weekend following the announcement of business results for the first quarter of 2016.
Spectrum Pharmaceuticals announced that the FDA has granted seven years of Orphan Drug exclusivity for Evomela.
Cara Therapeutics saw its shares jump early on Wednesday after it announced that it has received notice from the FDA that it has removed the clinical hold on its adaptive Phase 3 trial of I.V. CR845...
Gemphire Therapeutics has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
New research from Jefferies highlights this week's top growth stock picks, and there is a clear bias for some top biotech and pharmaceutical stocks — and with good reason. They are cheap and have...
Shares of Clovis Oncology dropped after the FDA Oncologic Drugs Advisory Committee voted against its lung cancer drug.
PTC Therapeutics saw its shares jump late Friday morning on positive news on its nonsense mutation Duchenne muscular dystrophy treatment.
Reata Pharmaceuticals has amended its filing with the U.S. Securities and Exchange Commission regarding its initial public offering.
The March 31 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks short interest was mixed.